The Chemotherapy Sourcebook
Michael C. Perry(Editor)
Lippincott Williams and Wilkins (Publisher)
2nd Edition
Published on 1. October 1996
Book
Hardback
1184 pages
978-0-683-06868-9 (ISBN)
Article exhausted; check for reprint
Description
Covering the science and practical use of chemotherapy as an integral part of cancer treatment, this edition includes material on intravesical therapy, differentiating agents, and anti-emetic and symptomatic drug treatments. Drug data sheets summarize chemotherapy agent information.
Covering the science and practical use of chemotherapy as an integral part of cancer treatment, this edition includes material on intravesical therapy, differentiating agents, and anti-emetic and symptomatic drug treatments. Drug data sheets summarize chemotherapy agent information.
Covering the science and practical use of chemotherapy as an integral part of cancer treatment, this edition includes material on intravesical therapy, differentiating agents, and anti-emetic and symptomatic drug treatments. Drug data sheets summarize chemotherapy agent information.
More details
Edition
2nd Revised edition
Language
English
Place of publication
Philadelphia
United States
Target group
Professional and scholarly
Edition type
Revised edition
Illustrations
71 illustrations
Dimensions
Height: 250 mm
Weight
2230 gr
ISBN-13
978-0-683-06868-9 (9780683068689)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions
Michael C. Perry
The Chemotherapy Source Book
Book
09/2001
3rd Edition
Lippincott Williams and Wilkins
€144.10
Article exhausted; check for reprint
Previous edition
Michael C. Perry
The Chemotherapy Sourcebook
Book
01/1977
Lippincott Williams and Wilkins
€194.62
Article exhausted; check for reprint
Persons
Content
Part 1 Principles of chemotherapy: scientific foundation of chemotherapy - the scientific basis of cancer chemotherapy, antineoplastic drug development, principles of pharmacology, drug resistance - the Norton-Simon hypothesis, drug resistance - the Goldie-Coldman hypothesis, adjuvant chemotherapy, combination chemotherapy, combined modality therapy, the design and interpretation of clinical trials, haematopoietic growth factors, biologic response modifiers - principles of immunotherapy, chemotherapy - circadian timing and toxicity; routes of administration - intraventricular therapy, intraperitoneal chemotherapy, continuous intravenous infusion chemotherapy, intraarterial therapy, perfusion therapy, bone marrow transplantation. Part 2 Chemotherapeutic drugs: covalent DNA-binding drugs; antimetabolites; non-covalent DNA-binding drugs; microtubule targeting drugs; taxanes; differentiating agents, hormonal agents; investigational drugs. Part 3 Management of drug toxicity: haematologic complications of cancer chemotherapy; oral toxicity; dermatological toxicity; extravasation; hypersensitivity reactions; ocular side effects of chemotherapy; the cardiotoxicity of chemotherapeutic drugs; antineoplastic drugs and pulmonary toxicity; gastrointestinal toxicity of chemotherapeutic agents; hepatotoxicity of chemotherapeutic agents; renal and electrolyte abnormalities due to chemotherapy; neurotoxicity of chemotherapeutic agents; vascular toxicity; second malignancies after chemotherapy; chemotherapy in pregnancy; gonadal toxicity and teratogenicity; toxicity of biologic response modifiers. Part 4 Combination chemotherapy programmes: combination chemotherapy programmes; central venous access for chemotherapy; safe handling of cytotoxic drugs - a review; stability and compatibility of intravenous oncology drugs; patient education; nursing implications in the administration of cancer chemotherapy. Part 5 Drug administration: myelodysplastic syndromes; myeloproliferative syndromes; the treatment of multiple myeloma and related plasma cell dyscrasias; appendix - WHO toxicity guidelines. Part 6 Current therapy of specific solid tumors: chemotherapy of melanoma; chemotherapy of primary brain tumors; head and neck cancer; chemotherapy of lung cancer; chemotherapy of breast cancer; chemotherapy of gastrointestinal cancer; chemotherapy of endocrine tumors; chemotherapy of genitourinary cancer; chemotherapy of gynaecologic cancer; sarcomas of bone and soft tissue; carcinoma of unknown primary site; paediatric solid tumors. Part 7 Chemotherapy of haematologic malignancies: Hodgkin's disease; non-Hodgkin's lymphoma; acute leukaemia in adults; chronic lymphocyte leukaemia and hairy cell leukaemia.